الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 73 |  |  |
| | | from | 73 | | |
Abstract
The study was conducted on 88 subjects recruited from The Tropical Medicine Department, Beni-Suef University Hospital in the years 2016-2017. The aim of the study was to evaluate sCD25 as a marker for the diagnosis of HCC and whether it correlates with the tumor stage.
Subjects were divided into three groups as follows:
group (1) HCC group which comprised (44) patients.
group (2) Cirrhotic group which comprised (32) patients.
group (3) Control group (12) healthy subjects.
The results of the study showed that:
1. The serum levels of both sCD25 and AFP were detected at a higher level in HCC patients than cirrhotic and control groups. However, there was no statistically significant difference between the three groups regarding s25CD and alpha-fetoprotein (P-value>0.05). 2. At a cut-off value of 1.1 pg/ml sCD25 has a sensitivity of 86.4% and specificity of 29.5% in detecting HCC.
3. sCD25 showed a higher sensitivity with lower specificity than AFP in predicting HCC presence. 4. As a marker for tumor stage, sCD25 had a lower sensitivity than AFP for early stage with no statistical significant correlation between tumor stage and both sCD25 and AFP.
5. As a marker for tumor size it showed a higher sensitivity with large sized tumors more than 5 cm with decreased sensitivity with small sized tumors less than 2 cm with no statistical significant correlation between tumor size and sCD25 and AFP.